期刊文献+

阿托伐他汀对大鼠造影剂肾病保护作用的实验研究 被引量:4

原文传递
导出
摘要 目的探讨阿托伐他汀对大鼠造影剂肾病是否有保护作用及最佳用药剂量。方法雄性SD大鼠48只随机分为空白对照组、实验对照组、造模组、阿托伐他汀1组、阿托伐他汀2组、阿托伐他汀3组共6组,每组8只,建立造影剂急性肾损伤大鼠模型,并按相应要求分别予不同药物及剂量干预。全自动生化分析仪检测造模前后血肌酐(Scr);光镜下肾组织病理观察并进行肾小管损伤半定量评分。结果 (1)注射造影剂48 h、72 h后造模组Scr较注射前均升高大于25%(P<0.05),提示造模成功;(2)空白对照组与实验对照组相应时间点Scr差异无统计学意义(P>0.05);(3)与造模组比较,阿托伐他汀1~3组注射造影剂48 h、72 h后血Scr有所下降,差异有统计学意义(P<0.05);(4)阿托伐他汀3组与阿托伐他汀1组、阿托伐他汀2组相比较,阿托伐他汀2组与阿托伐他汀1组相比较,注射泛影葡胺后48 h、72 h Scr均有下降,差异均有统计学意义(P<0.05);(5)造模组肾小管损伤评分明显高于对照组,差异均有统计学意义(P<0.05);阿托伐他汀组肾小管损伤评分低于造模组,差异有统计学意义(P<0.05);阿托伐他汀1~3组组间比较,随给药剂量增加,肾小管损伤评分逐渐下降,差异均有统计学意义(P<0.05);(6)肾小管损伤评分与阿托伐他汀剂量呈负相关性(r=-0.702,P<0.01)。结论阿托伐他汀对由造影剂引起的大鼠急性肾损伤有预防作用,且作用效果呈剂量依赖性。
作者 王君 戴春
出处 《中华临床医师杂志(电子版)》 CAS 2012年第17期5262-5265,共4页 Chinese Journal of Clinicians(Electronic Edition)
  • 相关文献

参考文献23

二级参考文献45

共引文献87

同被引文献20

  • 1韩雅玲.中国经皮冠状动脉介入治疗指南2012(简本)[J].中国医学前沿杂志(电子版),2012,4(12):50-59. 被引量:133
  • 2Nash K,Hafeez A,Hou S.Hospital-acquired renal insufficiency[J].Am J Kidney Dis,2002,39(5):930-936.
  • 3Mitchell AM,Jones AE,Tumlin JA,et al.Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting[J].J Am Soc Nephrol,2010,5(1):4-9.
  • 4Karlsberg RP,Dohad SY,Sheng R.Contrast-induced acute kidney injury(CI-AKI)following intra-arterial administration of iodinated contrast media[J].J Nephrol,2010,23(6):658-686.
  • 5Chuang FR,Chen TC,Wang IK,et al.Comparison of iodixanol and iohexol in patients undergoing intravenous pyelography:a prospective controlled study[J].Ren Fail,2009,31(3):181-188.
  • 6Furuichi K,Wada T,Iwata Y,et al.Administration of FR167653,a new anti-inflammatory compound,prevents renal ischaemia reperfusion injury in mice[J].Nephrol Dial Transplant,2002,17(3):399-407.
  • 7Li Y,Liu Y,Fu L,et al.Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy:a meta-analysis of seven randomized controlled trials[J].PLoS One,2012,7(4):e34450.
  • 8Poh KK,Liang S,Tan HC.Risk factors and clinical outcomes for contrast-induced nephropathy after percutaneous coronary intervention in patients with normal serum creatinine[J].Ann Acad Med Singapore,2010,39(5):374-380.
  • 9Patti G,Ricottini E,Nusca A,et al.Short-Term,High-Dose Atorvastatin Pretreatment to Prevent Contrast-Induced Nephropathy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention from the ARMYDA-CIN Trial[J].Am J Cardio,2011,108(1):1-7.
  • 10Ozhan H,Erden I,Ordu S,et al.Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography[J].Angiology,2010,61(7):711-714.

引证文献4

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部